CoChat
Sign Up
Cited by 86Thyroid Disorders and TreatmentsGrowth Hormone and Insulin-like Growth FactorsThyroid Cancer Diagnosis and Treatment

Studies of the Hormonal Regulation of Type 2 5′-Iodothyronine Deiodinase Messenger Ribonucleic Acid in Pituitary Tumor Cells Using Semiquantitative Reverse Transcription-Polymerase Chain Reaction**This work was supported by NIH Grant DK-36256.

Kim, Sung-Woo, Harney, John W., Larsen, P. Reed·1998·Endocrinology
DOI 10.1210/endo.139.12.6334
Open this paper in CoChat — free account

Abstract

We developed a sensitive competitive RT-PCR technique for quantitating the ratio of D2 to cyclophilin messenger RNA (mRNA) and used this to study type 2 deiodinase (D2) mRNA regulation. Hyperthyroidism in rats causes a 2- to 3-fold reduction in anterior pituitary and medial basal hypothalamus (MBH). Thyroid hormone (T3) withdrawal increased the D2/cyclophilin ratio 2- to 3-fold over 48 h in both GC and GH4C1 cells. T3 additional reduced D2 gene transcription by 50% over 2 h and about 30% over the next 2 h. D2 mRNA half-life is 2 h and is not affected by T3, indicating that its effect is due to suppression of D2 gene transcription. The T3 effect did not require new protein synthesis. Longer treatment with T3 led to a maximum decrease of 70% in D2 mRNA, indicating that there is also a T3-independent transcriptional component of the D2 gene. 3,3',5'-Triiodothyronine (reverse T3) caused a slight increase D2 mRNA over 24 h but an 80-90% decrease in D2 activity, indicating that it acts posttranscriptionally. Dexamethasone, 8 Br-cAMP, and TRH also caused modest increases in D2 mRNA in pituitary tumor cells. We conclude that D2 gene transcription has both T3-dependent and T3-independent components. Thus, posttranscriptional effects of D2 substrates such as T4 will be required for complete feedback inhibition of D2 activity. The short half-life of D2 mRNA and D2 protein explains the rapid response of D2 activity to thyroid hormone administration.

Integrity signals

Registry

Crossref · 10.1210/endo.139.12.6334

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • T3 represses gene transcription of DIO2, forming a negative feedback loop to keep intracellular T3 within a range.

    “T3 can repress the gene transcription of DIO2, the primary activating enzyme that converts T4 into T3, therefore forming a negative feedback loop to keep intracellular T3 within a range (30–32).”

    From Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion (2022) · cites this paper as [30]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kim, S.-W., Harney, J. W., & Larsen, P. R.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Larsen, P. Reed
Venue
Endocrinology
Publisher
The Endocrine Society
Published
1998-12-01
Volume
139
Issue
12
Pages
4895-4905
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
DOI
10.1210/endo.139.12.6334
OpenAlex
W1977026615
Cited by
86
References
3
Citations by year
2026: 3 · 2025: 1 · 2024: 5 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 2 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 3
FWCI
4.06
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK36256, R01DK036256)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
type 2 deiodinase, thyroid hormone regulation, mRNA regulation, cyclophilin, hyperthyroidism, thyroid hormone withdrawal, post-transcriptional regulation, mRNA half-life, reverse T3, dexamethasone, thyrotropin-releasing hormone, cyclic AMP, anterior pituitary, medial basal hypothalamus, pituitary tumor cells, GC cells, GH4C1 cells
MeSH terms
Animals, Dexamethasone, Hormones, Iodide Peroxidase, Isoenzymes, Male, Pituitary Neoplasms, RNA, Messenger, Thyrotropin-Releasing Hormone, Triiodothyronine, Triiodothyronine, Reverse, Tumor Cells, Cultured, 1-Methyl-3-isobutylxanthine, 8-Bromo Cyclic Adenosine Monophosphate, Blotting, Northern, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review